The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer.
L. J. Havrilesky
No relevant relationships to disclose
R. K. Hanna
No relevant relationships to disclose
M. S. Poniewierski
No relevant relationships to disclose
R. Laskey
No relevant relationships to disclose
A. A. Secord
No relevant relationships to disclose
P. A. Gehrig
No relevant relationships to disclose
M. A. Lopez
No relevant relationships to disclose
A. Shafer
No relevant relationships to disclose
L. Van Le
No relevant relationships to disclose
D. C. Dale
No relevant relationships to disclose
J. Crawford
Consultant or Advisory Role - Amgen
Research Funding - Amgen
G. H. Lyman
Research Funding - Amgen